Cited by 136Retinal Diseases and TreatmentsAlzheimer's disease research and treatmentsRetinal Development and Disorders

β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment

Open access
Cai, Jun, Qi, Xiaoping, Kociok, Norbert, Skosyrski, Sergej, Emilio, Alonso, Ruan, Qing, Han, Song, Liu, Li +9 more·2012·EMBO Molecular Medicine

Abstract

β-Secretase (BACE1) is a major drug target for combating Alzheimer's disease (AD). Here we show that BACE1(-/-) mice develop significant retinal pathology including retinal thinning, apoptosis, reduced retinal vascular density and an increase in the age pigment, lipofuscin. BACE1 expression is highest in the neural retina while BACE2 was greatest in the retinal pigment epithelium (RPE)/choroid. Pigment epithelial-derived factor, a known regulator of γ-secretase, inhibits vascular endothelial growth factor (VEGF)-induced in vitro and in vivo angiogenesis and this is abolished by BACE1 inhibition. Moreover, intravitreal administration of BACE1 inhibitor or BACE1 small interfering RNA (siRNA) increases choroidal neovascularization in mice. BACE1 induces ectodomain shedding of vascular endothelial growth factor receptor 1 (VEGFR1) which is a prerequisite for γ-secretase release of a 100 kDa intracellular domain. The increase in lipofuscin following BACE1 inhibition and RNAI knockdown is associated with lysosomal perturbations. Taken together, our data show that BACE1 plays a critical role in retinal homeostasis and that the use of BACE inhibitors for AD should be viewed with extreme caution as they could lead to retinal pathology and exacerbate conditions such as age-related macular degeneration.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/emmm.201101084

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Germline and adult conditional BACE1 knockout mice show complex neurological phenotypes.

    “Indeed, germline and adult conditional BACE1 knockout mice display complex neurological phenotypes.”

    From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [67]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 36 · Cited by 136

Authors
Cai, J., Qi, X., Kociok, N., Skosyrski, S., Emilio, A., Ruan, Q., Han, S., Liu, L., Chen, Z., Bowes Rickman, C., Golde, T., Grant, M. B., Saftig, P., Serneels, L., de Strooper, B., Joussen, A. M., & Boulton, M. E.
Affiliations
  • University of Florida (US)
  • Charité – Universitätsmedizin Berlin (DE)
  • Vlaams Instituut voor Biotechnologie (BE)
Corresponding author
Boulton, Michael E.
Venue
EMBO Molecular Medicine
Published
2012-08-20
Volume
4
Issue
9
Pages
980-991
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2138206059
Cited by
136
References
36
Citations by year
2026: 2 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 8 · 2021: 5 · 2020: 10 · 2019: 11 · 2018: 10 · 2017: 12 · 2016: 18 · 2015: 8 · 2014: 20 · 2013: 19 · 2012: 2
FWCI
14.96
Type
journal article
Language
en
Open access
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
  • Lirias (submittedVersion)
Funders
  • NIH (EY018358, EY019688)
  • AHAF (M2009024)
  • Funded Access
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
Keywords
BACE1, beta-secretase inhibition, retinal disease, lipofuscin accumulation, retinal vessel density, choroidal neovascularization, VEGF-induced angiogenesis, gamma-secretase, retinal pigment epithelium, age-related macular degeneration
MeSH terms
Animals, Enzyme Inhibitors, Female, Lipofuscin, Lysosomes, Mice, Inbred C57BL, Retina, Aspartic Acid Endopeptidases, Mice, Knockout, Choroidal Neovascularization, Gene Silencing, Mice, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review